In autoimmune neutropenia most patients produce IgG antibodies against neutrophils.' During pregnancy IgG antibodies are transported by the human placenta from the maternal into the fetal circulation. Thus transient neonatal neutropenia could develop in children of women with active autoimmune neutropenia, a syndrome that may be associated with severe infections in the neonatal period. This possibility has never been described nor has the passage of the autoantibodies through-the placental barrier been shown. We used the granulocyte immunofluorescence test' to diagnose the autoimmune character of neutropenia in a mother and the association of raised granulocyte-bound IgG concentration and transient neutropenia in the child. This test is based on the observation that aspecific fluorescence may be prevented by fixing the granulocytes with paraformaldehyde. Specific antiglobulin Fab reagents labelled with fluorescein isothiocyanate were used.
Case report
A 20 year old woman presented with a short history of skin infections and buccal ulcerations. She had no history of systemic illness, and physical examination showed no abnormalities. Neutropenia was diagnosed. The bone marrow aspirate showed a ratio of myeloid to erythroid of 8 to 1, normal cellularity, and normal myeloid precursors with a relative deficit of segmented neutrophils. There were no other haematological abnormalities. The granulocyte immunofluorescence test showed IgG autoantibodies against neutrophils. Granulocyte-specific antibodies in serum were shown by testing it in the indirect immunofluorescence test with granulocytes, platelets, and lymphocytes from the same donors. The autoantibodies were not specific for any blood group. Tests for antinuclear factor gave negative results. A presumptive diagnosis of autoimmune neutropenia was made. She failed to respond to an adequate course of steroid and azathioprine treatment.
At the age of 24 she became pregnant. Her antenatal progress was normal and an apparently healthy boy was born at term. Umbilical cord blood showed a very low neutrophil count and IgG antibodies to neutrophils were detectable on cord blood neutrophils with the direct granulocyte immunofluorescence test and in the cord blood serum with the indirect test. There were no other haematological abnormalities. On the second day prophylactic treatment with co-trimoxazole and nyastatin was started. On the third day the child developed a pustula and an umbilical infection due to Staphylococcus aureus, which was successfully treated with oral cephradine. The child was discharged after two weeks. After 16 weeks the neutrophil count came within normal limits and the direct granulocyte immunofluorescence test gave negative results, after which the prophylactic co-trimoxazole and nystatin treatment was stopped ( figure) . No other infections occurred in the neutropenic period and the child grew and developed normally. 
Comment
Thirty years ago it was suggested that a humoral factor was the causative agent in idiopathic thrombocytopenic purpura after the observation that mothers with the disease give birth to children who develop transient thrombocytopenia.2 The suspected platelet autoantibodies and their transfer through the placenta has recently been confirmed.3 This first reported transient neonatal neutropenia supports the presumptive diagnosis of maternal autoimmune neutropenia. Moreover, we confirmed the presence of suspected IgG autoantibodies against neutrophils and their transfer through the placenta. The transient character of the neutropenia and the gradual disappearance of antibodies from the neutrophils in the child supports the theory that antibodies were passively acquired.
Antibiotic prophylaxis with co-trimoxazole and nystatin is recommended in patients with neutropenia.' The use of co-trimoxazole in infancy is disputed, however,5 and there is no experience in large series of infants. We observed no side effects and apart from the short lasting skin infection during the first week, no infections occurred during the neutropenic phase. This could be ascribed to this prophylactic treatment. Nephrotic syndrome after treatment with psoralens and ultraviolet A
In an attempt to desensitise a case of polymorphic light eruption with psoralens-ultraviolet A (PUVA) treatment the patient developed nephrotic syndrome at the end of treatment. The temporal relation between the two events suggests that PUVA treatment was of pathogenetic importance in the development of the nephrotic syndrome.
Case report
A 38 year old white woman had a history of polymorphic light eruption since the age of 10 years. In 1970 she was treated with trimethoxypsoralen (Trisoralen)l and was told to expose herself to increasing amounts of sunlight. This treatment was beneficial and there were no side effects. Further treatment with topical sunscreening agents, oral a carotene, and ultraviolet B produced no appreciable improvement. Between 1970 and 1982 her renal function was normal without proteinuria on several occasions.
In July 1982 she wsas given PUVA treatment twice weekly for five weeks.
At the end of August 1982 she developed peripheral oedema and was found to have the nephrotic syndrome with a serum albumin concentration of
